Immune Biosolutions Participating in Futurpreneur’s Growth Accelerator
After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator…
After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator…
CQDM to support a $1.1 million research and development project for Immune Biosolutions’ next-generation of anti-cancer treatment BOSTON, JUNE 6,…
Immune Biosolutions has been selected to present at the 7th International Cancer Cluster Showcase 2018 in Boston during the BIO Convention…
Immune Biosolutions’ team will once again participate to one of the largest life sciences convention in North America. Frédéric Leduc,…
Chief Executive Officer, Frédéric Leduc, and Chief Scientific Officer, Simon Gaudreau, will be representing Immune Biosolutions next week at the 14th…
Immune Biosolutions, a Canadian biotech company specialized in the discovery and engineering of humanized chicken antibodies, will present its proprietary Nebula Discovery platform…
Immune Biosolutions selected for JLABS @ Toronto Immune Biosolutions is among the 22 growing businesses selected for JLABS @ Toronto….
Immune Biosolutions, a JLABS @ Toronto resident, is pleased to announce the relocation of its Sherbrooke headquarters and laboratories in…
Why target GPCRs with antibodies? The G Protein-coupled receptor (GPCR) superfamily represents the largest and single most important family of…